This panel will discuss some of the challenges and opportunities facing the FDA as it conducts inspectional oversight following the termination of the Public Health Emergency, including the continued role of alternative inspection tools, the backlog of postponed surveillance inspections, the anticipated impacts of the proposed ORA reorganization on inspections and compliance activity, and the implementation of GDUFA III inspection related commitments.